| Literature DB >> 24719873 |
Ruqaya Mustafa Ali1, Alberto Trovato2, David Couvin3, Amina N Al-Thwani1, Emanuele Borroni2, Fahim H Dhaer4, Nalin Rastogi3, Daniela M Cirillo2.
Abstract
Tuberculosis (TB) remains a major health problem in Iraq but the strains responsible for the epidemic have been poorly characterized. Our aim was to characterize the TB strains circulating in Bagdad (Iraq). A total of 270 Mycobacterium tuberculosis complex (MTBC) strains isolated between 2010 and 2011 from TB patients attending the Center of Chest and Respiratory diseases in Baghdad were analyzed by Spoligotyping. The analysis indicated that 94.1% of the isolates belong to known genotype clades: CAS 39.6%, ill-defined T clade 29.6%, Manu 7.4%, Haarlem 7%, Ural 4.1%, LAM 3.3%, X 0.7%, LAM7-TUR 0.7%, EAI 0.7%, S 0.7%, and unknown 5.9%. Comparison with the international multimarker database SITVIT2 showed that SIT 309 (CAS1-Delhi) and SIT1144 (T1) were the most common types. In addition, 44 strains were included in SITVIT2 database under 16 new Spoligotype International Types (SITs); of these, 6 SITs (SIT3346, SIT3497, SIT3708, SIT3790, SIT3791, and SIT3800) (n = 32 strains) were created within the present study and 10 were created after a match with an orphan in the database. By using 24-loci MIRU-VNTR-typing on a subset of 110 samples we found a high recent transmission index (RTI) of 33.6%. In conclusion, we present the first unifying framework for both epidemiology and evolutionary analysis of M. tuberculosis in Iraq.Entities:
Mesh:
Year: 2014 PMID: 24719873 PMCID: PMC3955663 DOI: 10.1155/2014/580981
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic characteristics of the population studied and drug resistance profiles.
| Parameters | Origin of patients | ||
|---|---|---|---|
| Baghdad (%) | Other governorates (%) | Total | |
| Total no. of strain | 157 (58.1) | 113 (41.9) | 270 |
| Sex | |||
| Male | 94 ( 59.9) | 85 (75.2) | 179 |
| Female | 63 (40.1) | 28 (24.8) | 91 |
| Sex ratio M : F | 1.49 | 3.04 | 1.97 |
| Age group (yr) (no.) | |||
| 0–20 | 17 (10.8) | 4 (3.5) | 21 |
| 21–40 | 82 (52.2) | 71 (62.8) | 153 |
| 41–60 | 48 (30.6) | 25 (22.1) | 73 |
| >60 | 10 (6.4) | 13 (11.5) | 23 |
| Smear microscopy (no.) | |||
| Positive | 98 (62.4) | 69 (61.1) | 167 (61.8) |
| Negative | 59 (37.6) | 44 (38.9) | 103 (38.2) |
| Treatment | |||
| New cases | 119 (75.8) | 68 (60.2) | 187 (69.3) |
| P.T.C | 38 ( 24.2) | 45 (39.8) | 83 (30.7) |
| Drug susceptibility | |||
| Susceptible to all drugs | 102 (65) | 69 (61.1) | 171 (63.3) |
| MDR (INH − RIF) | 31 (19.8) | 33 (29.2) | 64 (23.7) |
| Unknown | 24 (15.3) | 11 (9.7) | 35 (13.0) |
Orphan strains (n = 53) and corresponding spoligotyping defined lineages/sublineages recorded among a total of 270 M. tuberculosis strains (one isolate per patient) from Iraqi patients.
|
|
*Lineage designations for orphan patterns were done manually as expert-based interpretations using revised SpolDB4 rules.
**Drug resistance (drug R) information is shown as 0, unknown; 1, non-MDR; 2, MDRTB, that is, combined resistance to INH − RIF (with or without resistance to other drugs); 3, any other resistance(s); 4, proven XDRTB, that is, resistance to INH + RIF + a fluoroquinolone + any 1 of 3 injectable 2nd-line drugs (capreomycin, kanamycin, amikacin).
Description of 64 shared types (SITs; n = 217 isolates) and corresponding spoligotyping defined lineages/sublineages starting from a total of 270 M. tuberculosis strains isolated from Iraqi patients.
|
|
*A total of 48/64 SITs containing 173 isolates matched a preexisting shared type in the database, whereas 16/64 SITs (n = 44 isolates) were newly created. A total of 31/64 SITs containing 184 isolates were clustered within this study (2 to 17 isolates per cluster) while 33/64 SITs containing 33 strains were unique (for total unique strains, one should add to this number the 53 orphan strains, which brings the number of unclustered isolates in this study to 86/270 or 31.85% and clustered isolates to 184/270 or 68.15%). Note that SITs followed by an asterisk indicates “newly created” SITs due to 2 or more strains belonging to an identical new pattern within this study or after a match with an orphan in the database; SIT designations followed by number of strains: 3275* this study n = 1, FXX n = 1; 3346* this study n = 11; 3497* this study n = 8; 3708* this study n = 3; 3789* this study n = 2, IRQ n = 1; 3790* this study n = 4; 3791* this study n = 4; 3792* this study n = 2, IND n = 1; 3793* this study n = 1, IND n = 1; 3794* this study n = 1, IND n = 1; 3795* this study n = 1, BRA n = 1; 3796* this study n = 1, PAK n = 1; 3797* this study n = 1, MEX n = 1; 3798* this study n = 1, IRQ n = 1; 3799* this study n = 1, BRA n = 1; 3800* this study n = 2.
**Lineage designations according to SITVIT2 using revised SpolDB4 rules; “unknown” designates patterns with signatures that do not belong to any of the major lineages described in the database.
***Clustered strains correspond to a similar spoligotype pattern shared by 2 or more strains “within this study,” as opposed to unique strains harboring a spoligotype pattern that does not match with another strain from this study. Unique strains matching a preexisting pattern in the SITVIT2 database are classified as SITs, whereas in case of no match, they are designated as “orphan” (see Table 2).
Figure 1A minimum spanning tree (MST) illustrating evolutionary relationships between the Mycobacterium tuberculosis spoligotypes. This kind of tree connects each genotype based on degree of changes required to go from one allele to another. The structure of the tree is represented by branches (continuous versus dashed and dotted lines) and circles representing each individual pattern. Note that the length of the branches represents the distance between patterns while the complexity of the lines (continuous, gray dashed, and gray dotted) denotes the number of allele/spacer changes between two patterns: solid lines represent 1, 2, or 3 changes (thicker ones indicate a single change, while the thinner ones indicate 2 or 3 changes); gray dashed lines represent 4 changes; and gray dotted lines represent 5 or more changes. The size of the circle is proportional to the total number of isolates in our study, illustrating unique isolates (smaller nodes) versus clustered isolates (bigger nodes). The color of the circles indicates the phylogenetic lineage to which the specific pattern belongs. Note that orphan patterns are circled in orange. Patterns colored in cyan-blue indicate a strain with an unknown signature (unclassified).
Description of clusters containing 5 or more isolates in this study and their worldwide distribution in the SITVIT2 database.
|
|
*Worldwide distribution is reported for regions with more than 3% of a given SITs as compared to their total number in the SITVIT2 database. The definition of macrogeographical regions and subregions (http://unstats.un.org/unsd/methods/m49/m49regin.htm) is according to the United Nations; regions: AFRI (Africa), AMER (Americas), ASIA (Asia), EURO (Europe), and OCE (Oceania) are subdivided in E (eastern), M (middle), C (central), N (northern), S (southern), SE (south eastern), and W (western). Furthermore, CARIB (caribbean) belongs to Americas, while Oceania is subdivided in 4 subregions, AUST (Australasia), MEL (Melanesia), MIC (Micronesia), and POLY (Polynesia). Note that in our classification scheme, Russia has been attributed a new subregion by itself (northern Asia) instead of including it among the rest of eastern Europe. It reflects its geographical localization as well as due to the similarity of specific TB genotypes circulating in Russia (a majority of Beijing genotypes) with those prevalent in central, eastern, and south eastern Asia.
**The 3 letter country codes are according to http://en.wikipedia.org/wiki/ISO_3166-1_alpha-3; countrywide distribution is only shown for SITs with ≥3% of a given SITs as compared to their total number in the SITVIT2 database.
Figure 2UPGMA tree based on MIRU 24 pattern of the subset of 110 samples. Drug resistance (Drug R) information is shown as 0, unknown; 1, non-MDR; 2, MDR-TB, that is, combined resistance to INH-RIF (with or without resistance to other drugs).
Figure 3A minimum spanning tree (MST) illustrating evolutionary relationships between the M. tuberculosis spoligotypes in our study in function to studied parameters. (a) Drug resistance and (b) treatment status, that is, new versus retreated cases.